Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034

Executive Summary

Country Wise- Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Epidemiology

Estimates show the highest Incident population of ALK NSCLC is in the United States. Furthermore, among the European 5 countries, the Germany had highest incident population of NSCLC.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Drug Chapters

Drug chapter segment of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer report encloses the detailed analysis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Marketed Drugs

Xalkori (Crizotinib): Pfizer
Xalkori (Crizotinib), an ALK inhibitor, was first-ever approved treatment for metastatic NSCLC by the US FDA. This product received accelerated approval in 2011. The US FDA approval of Xalkori is based on data from 255 patients with locally advanced or metastatic ALK-positive NSCLC across two multicenter, single-arm studies, including a Phase II study (PROFILE 1005) and a Part 2 expansion cohort of a Phase I study (Study 1001).

Alunbrig (Brigatinib): Takeda
Alunbrig (Brigatinib) was approved by the US FDA in April 2017 for the treatment of patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to Crizotinib. In the year 2018, the European Commission (EC) also granted marketing authorization for Alunbrig as a monotherapy for the treatment of adult patients with ALK+ NSCLC previously treated with Crizotinib. In April 2020, the European Commission (EC) extended the current marketing authorization of Alunbrig to include use as a monotherapy for the treatment of adult patients with ALK+ advanced NSCLC previously not treated with an ALK inhibitor. This decision came after a positive opinion from the CHMP on February 27, 2020.

Products detail in the report.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Emerging Drugs

Ensartinib: Xcovery Holding Company
Xcovery is investigating their drug candidate, Ensartinib which is a potential best-in-class oral compound for the first-line treatment of ALK-positive NSCLC. This product has additional activity against MET, ABL, Axl, EPHA2, LTK, ROS1, and SLK. In phase I/II clinical trial, this product has shown promising activity in both ALK TKI naïve and crizotinib-resistant ALK+ NSCLC patients. Ensartinib is generally well tolerated with the most common toxicities being rash and nausea/vomiting, the latter often resolved with food.

At present, a global Phase III clinical trial (eXalt3) is ongoing comparing Ensartinib to Crizotinib in TKI naïve ALK-positive NSCLC patient. The primary purpose of this study is to evaluate the efficacy and safety of ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to one prior chemotherapy regimen and no prior ALK inhibitor.

Products detail in the report.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Outlook

Key Findings

According to the publisher, Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017-2030. The therapeutic market of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in seven major markets was found to be USD 841 million in 2017 which is expected to increase during study period (2017-2030).

The United States Market Outlook

In 2017, the total market size of ALK NSCLC therapies was found to be USD 422 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of ALK NSCLC therapies was found to be USD 267 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of ALK NSCLC therapies in Japan was found to be USD 152 million in 2017.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Development Activities

The drugs which are in pipeline includes:
1. Ensartinib: Xcovery Holding Company: Phase III

Products detail in the report.

Pipeline Development Activities

Key Points

1. At present, a global Phase III clinical trial (eXalt3) is ongoing comparing Ensartinib to Crizotinib in TKI naïve ALK-positive NSCLC patient. The primary purpose of this study is to evaluate the efficacy and safety of ensartinib vs. crizotinib in patients with ALK-positive NSCLC that have received up to one prior chemotherapy regimen and no prior ALK inhibitor.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Drugs Uptake

The current market is dominated by Alecensa (alectinib) which is expected to generate its peak revenue in coming years, and after that its revenue is expected to decline. This decline is a majorly attributed due to the presence of Lorbrena (because it is targeting the patient pool which is refractory to Crizotinib, Alectinib, and Ceritinib.

Access and Reimbursement Scenario in Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Therapies

• In 2018, Alecensa was recommended, within its marketing authorization, for untreated patients with NSCLC, whose tumors are identified as ALK-positive. Alecensa demonstrated considerable improvements in delaying cancer growth in enrolled patients. It has also shown significant improvements in preventing and delaying cancer spread into the brain.
• This decision was entirely based on data from the Phase III ALEX study, which showed a reduction in the risk of disease worsening, or death by 57% compared with standard of care Xalkori.

KOL - Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Anaplastic lymphoma kinase Non-Small Cell Lung Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• Comprehensive insight has been provided into the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.

Report Highlights

• In the coming years, Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic lymphoma kinase Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer. Launch of emerging therapies, will significantly impact the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Insights

• Patient Population
• Therapeutic Approaches
• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Pipeline Analysis
• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Key Strengths

• 11 Years Forecast
• 7MM Coverage

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Epidemiology Segmentation

• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Report Assessment

• SWOT Analysis
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Conjoint Analysis
• Market Attractiveness
• Market Drivers and Barriers

Key Questions Answered

Market Insights:

• What was the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer total market Size as well as market size by therapies across the 7MM during the study period (2017-2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market size during the study period (2017-2030)?
• At what CAGR, the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market is expected to grow in the 7MM during the study period (2017-2030)?
• What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market outlook across the 7MM during the study period (2017-2030)?
• What would be the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
• Anaplastic lymphoma kinase Non-Small Cell Lung Cancer patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
• How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
• Among the emerging therapies, what are the potential therapies which are expected to disrupt the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• What is the historical Anaplastic lymphoma kinase Non-Small Cell Lung Cancer patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What would be the forecasted patient pool of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• Out of all the 7MM countries, which country would have the highest Incident population of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer during the study period (2017-2030)?
• At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer along with the approved therapy?
• What are the current treatment guidelines for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in the US, Europe and Japan?
• What are the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• How many therapies are developed by each company for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• How many emerging therapies are in mid stage, and late stage of development for the treatment of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer and their status?
• What are the key designations that have been granted for the emerging therapies for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?
• What are the global historical and forecasted market of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
• To understand the future market competition in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.
• To understand the future market competition in the Anaplastic lymphoma kinase Non-Small Cell Lung Cancer market.

• Hoffmann-La Roche
• Takeda Pharmaceuticals
• Xcovery